Rheumatology: Recent Episodes
ReachMD
Guest: Martin Cheatle, PhD
A thoughtful, communicative, and compassionate approach to opioid use is essential for responsible patient use. Join Dr. Martin Cheatle as he explains the neuroscience of chronic pain, the psychosocial components often overlooked in these patients, and evidence-based strategies for evaluating risk and treatment response. Dr. Cheatle is the Director of Behavioral Medicine at the Penn Pain Medicine Center as well as an Associate Professor of Psychiatry, Anesthesiology, and Critical Care and the Director of Pain and Chemical Dependency Research at the Center for Studies of Addiction at the University of Pennsylvania. He also presented on this topic at the 2025 Congress of Clinical Rheumatology East conference.
Guest: Michelle Kahlenberg, MD, PhD
Lupus arises from a complex interaction of genetics, environmental stimuli, and immune system errors. Dive into the pathophysiology behind the disease with Dr. Michelle Kahlenberg, the Giles Boles and Dorothy Mulkey Research Professor of Rheumatology and Professor of Internal Medicine and Dermatology at the University of Michigan, as she examines the mechanisms that contribute to the development of autoreactive immune responses. Dr. Kahlenberg also spoke about this topic at the 2025 Congress of Clinical Rheumatology East conference.
Guest: John Bridges, MD, MS
For children with rheumatic diseases, early diagnosis, personalized care, and multidisciplinary collaboration are critical for optimal long-term management. Join Dr. John Bridges, Assistant Professor in the Division of Pediatric Rheumatology at the University of Alabama at Birmingham Heersink School of Medicine, as he explains how access, timing, and collaboration shape pediatric rheumatology care. Dr. Bridges presented on this topic at the 2025 Congress of Clinical Rheumatology East conference.
Guest: Michelle Kahlenberg, MD, PhD
Our approach to lupus management is accelerating, with emerging results on targeted therapies in skin and renal disease showing promise. Dr. Michelle Kahlenberg shares insights on emerging biologics, CAR-T innovations, and potential barriers in translating treatment breakthroughs into real-world patient care. Dr. Kahlenberg is the Giles Boles and Dorothy Mulkey Research Professor of Rheumatology and a Professor of Internal Medicine at Dermatology at the University of Michigan, and she spoke about this topic at the 2025 Congress of Clinical Rheumatology East conference.
Guest: Laura Cappelli, MD, MHS,MS
Patients who are receiving immunotherapy for cancer sometimes develop significant autoimmune complications, which can be fatal. Join Dr. Laura Cappelli, Associate Professor of Medicine and Oncology at the Johns Hopkins University School of Medicine, as she explains how multidisciplinary collaboration can help manage these rheumatic immune-related adverse events (irAEs). Dr. Cappelli also spoke about this topic at the 2025 Congress of Clinical Rheumatology East conference.
Guest: Andre Harvin, PharmD, MS, MBA
Biosimilars have greatly impacted the US healthcare system over the last decade, creating cost savings and increasing access for patients.1,2 However, although some biosimilars have seen significant adoption, not all biosimilars have been able to achieve sustainable market use.1 Learn about the barriers to biosimilar adoption in the US and strategies for overcoming them from Dr. Andre Harvin. Dr. Harvin is the chief pharmacy officer at Cone Health in Greensboro, North Carolina.
References:
- AAM, The U.S. Generic & Biosimilar Medicines Savings Report, September 2023
- IQVIA Institute for Human Data Science, Biosimilars in the United States 2023-2027: Competition, Savings, and Sustainability, January 2023
© Fresenius Kabi USA, LLC 2025 03/2025
Guest: Atul A. Deodhar, MD, MRCP
Based on data from 25 studies, ixekizumab has a lower risk of common adverse events like depression, cardiovascular events, cancer, and uveitis that are often seen with other treatments for psoriasis, psoriatic arthritis, and axial spondyloarthritis. Here to share the safety findings on ixekizumab is Dr. Atul Deodhar, Professor of Medicine and the Medical Director of Rheumatology Clinics at Oregon Health & Science University
Guest: Atul A. Deodhar, MD, MRCP
Despite feeling some symptom relief with treatment, patients with psoriasis, psoriatic arthritis, and axial spondyloarthritis often experience persistent unmet needs. Residual pain, fatigue, and uncertainty about whether current therapies alter disease progression and outcomes are a few of the challenges that remain unaddressed, emphasizing the need for improved understanding and management of these conditions. Learn about how these difficulties impact patients with Dr. Atul Deodhar, Professor of Medicine and Medical Director of Rheumatology Clinics at Oregon Health & Science University.
Guest: Robin Dore, MD
Despite the challenges of managing rheumatoid arthritis—especially for patients with difficult-to-treat cases or a history of cancer—clinical trials, updated guidelines, and data-driven decision-making are helping to shape the future of care. Dive deeper into how rheumatoid arthritis treatment is evolving with Dr. Robin Dore, board-certified rheumatologist and Invited Lecturer at the University of California, Irvine in the Division of Rheumatology.
Guest: Robin Dore, MD
Rheumatoid arthritis presents uniquely in every patient, which can make treatment decisions complex. As a result, it’s important to balance factors like symptom variations, patient concerns, and medical guidelines to find the right approach. Hear how risk-benefit discussions and evolving treatment strategies can shape care from Dr. Robin Dore, a board-certified rheumatologist and an Invited Lecturer at the University of California, Irvine in the Division of Rheumatology.
Host: William D. Tap, MD
Host: John Healey, MD
In this activity, a medical oncologist and orthopedic surgeon discuss evidence-based surgical and systemic therapy approaches for the treatment of tenosynovial giant cell tumors (TGCT). Topics include differentiating TGCT by presentation; surgical candidacy, approaches, and limitations; systemic treatment options with CSF1R inhibitors; and considerations for treatment selection with surgical, nonsurgical, or combination interventions. A patient case example is used to demonstrate optimal multidisciplinary and patient-centered treatment considerations and selection. Strategies for multidisciplinary collaboration to ensure comprehensive monitoring and effective disease management are also explored. Tune in to find out how to enhance the collaborative capacity of multidisciplinary teams in developing individualized, patient-centered treatment plans for patients with TGCT.
Vimseltinib is now FDA-approved for adult patients with symptomatic TGCT, for which surgical resection will potentially cause worsening functional limitation or severe morbidity. This activity was recorded prior to this FDA approval.
Guest: Leonard H. Calabrese, DO
With at least 4 percent of patients who experience COVID-19 developing long COVID, improving care for post-infectious chronic conditions is critical. By prioritizing research and education on the rheumatological effects of acute infections, we can address these patients’ unmet needs. Join Dr. Leonard Calabrese, Vice Chairman of the Department of Rheumatic and Immunologic Disease and Head of Clinical Immunology at the Cleveland Clinic Foundation, as he explains what we know so far about these conditions.
Guest: Atul A. Deodhar, MD, MRCP
Managing psoriasis, psoriatic arthritis, and axial spondyloarthritis with ixekizumab may cause adverse effects in patients. That’s why a recent research review further investigated the safety of this treatment over time, analyzing data from 25 clinical trials and noting common side effects. Learn more about ixekizumab’s long-term use with Dr. Atul Deodhar, the lead author of this study. He’s also a Professor of Medicine and the Medical Director of Rheumatology Clinics at Oregon Health & Science University.
Guest: Philip J. Mease, MD, MACR
Managing pain in chronic rheumatic conditions requires a comprehensive approach. Through education and innovative research, we can develop more effective ways to care for patients. Dr. Philip Mease, Director of Rheumatology Research at Swedish Medical Center and Clinical Professor at the University of Washington School of Medicine, gives a preview into the future of pain management.
Guest: Philip J. Mease, MD, MACR
Chronic pain isn’t always caused by inflammation—in rheumatic conditions, nociplastic and neuropathic pain can both complicate treatment. Understanding these pain types is crucial to effective patient management. Dr. Philip Mease, Director of Rheumatology Research at Swedish Medical Center in Seattle and Clinical Professor at the University of Washington School of Medicine, explains the complexities behind each type of pain and key considerations for patient care.
Host: Claire Gill
Guest: Andrea Singer, MD, FACP, CCD
Menopause accelerates bone loss due to declining estrogen levels, increasing the risk of osteoporosis and fractures. To learn how we can best support bone health during this transition, CEO of the Bone Health and Osteoporosis Foundation Claire Gill speaks with Dr. Andrea Singer, Chief Medical Officer of the Bone Health and Osteoporosis Foundation, Professor of Medicine and Obstetrics and Gynecology at MedStar Georgetown University Hospital, and a member of the National Menopause Foundation's Medical Advisory Committee.
This program contains important information about the limitations of current therapies used to treat plaque psoriasis. Drs. Kim Papp and Jerry Bagel discuss these shortcomings and outline clinical data on investigational oral medications for plaque psoriasis.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: William F.C. Rigby, MD
Polymyalgia rheumatica (PMR) is an inflammatory rheumatic condition that can be difficult to diagnose and treat. For instance, PMR is a diagnosis of exclusion, and it can mimic a wide variety of other conditions. And once a patient is accurately diagnosed, the standard-of-care treatment with glucocorticoids may result in toxicity for some patients. Learn more about these and other diagnostic and treatment challenges as well as other treatment options with Dr. Charles Turck and Dr. William Rigby, Professor of Medicine and of Microbiology and Immunology at the Geisel School of Medicine at Dartmouth.
© 2024 Sanofi and Regeneron Pharmaceuticals, Inc.
All rights reserved.
MAT-US-2403256 v1.0 - P
Expiration Date 04/16/2025
Guest: Jason Busse, PhD
In light of the opioid epidemic, the use of cannabis for therapeutic purposes is becoming of interest. But since there are other alternatives that are often more effective and have better safety profiles, it’s important to understand the evidence and guideline recommendations around these two treatment options. Here to share key considerations for using opioids and cannabis to treat patients living with chronic pain is Dr. Jason Busse, who presented a session on this exact topic at the 2024 Congress of Clinical Rheumatology.
Guest: Jason Busse, PhD
Different clinical practice guidelines often have discrepancies from one another, making it a challenge for clinicians to determine which ones are more trustworthy. Here to break down the things clinicians should look for when sorting between guidelines that give discrepant recommendations is Dr. Jason Busse, who presented a session on this exact topic at the 2024 Congress of Clinical Rheumatology.
Host: Michael Lewiecki, MD, FACP, FACE
Although step therapy is the approach that many health plans and organizations are fond of, individualizing treatment decisions for patients with osteoporosis is essential, especially those who are at risk of fractures. To learn how you can create personalized treatment plans for patients with osteoporosis, tune in to hear Dr. Michael Lewiecki give us a recap of the session he presented at the 2024 Congress of Clinical Rheumatology.
Host: Michael Lewiecki, MD, FACP, FACE
Here to talk about current concepts in the management of osteoporosis like insurance coverage, therapy sequencing, and comparative effectiveness is Dr. Michael Lewiecki, who presented a session on this exact topic at the 2024 Congress of Clinical Rheumatology.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: John Stone, MD, MPH
Glucocorticoids are often successfully used as the mainstay of treatment for many inflammatory conditions, but adverse events associated with glucocorticoids use are common. Fortunately, there are steps we can take to reduce the risk of glucocorticoid toxicity, like monitoring patients, educating them on the possible side effects, and considering alternative treatments where available. Tune in to learn more about the side effects, risk factors, and prevention strategies with Dr. Charles Turck and Dr. John Stone.
© 2024 Sanofi and Regeneron Pharmaceuticals, Inc. All rights reserved.
MAT-US-2310647 v1.0 - P
Expiration Date 04/16/2025
Host: John K. Botson, MD, RPh
Guest: Xu He, MD
Many patients with gout don’t achieve their target urate levels with conventional urate-lowering therapies. Join renowned experts Drs. Xu He and John Botson as they dissect the potential benefits of urate reduction, discuss management options for patients with uncontrolled gout, and underscore the critical significance of timely referrals from primary care to specialty care in optimizing outcomes for patients with uncontrolled gout.
Guest: Cara Dolin, MD
Guest: Jennifer Simpson
Guest: Diana Girnita, MD ,PhD
Explore this video roundtable featuring an interdisciplinary panel of experts discussing a woman’s journey with mycophenolate therapy and strategies to approach risk mitigation. Learn more about how to provide critical education on the risks of mycophenolate, the importance of effective contraception, and navigating family planning.
Host: Abdul Abdellatif, MD, FASN
Guest: John K. Botson, MD, RPh
Conventional oral urate-lowering therapies frequently to fail to achieve target serum uric acid (sUA) levels in patients with chronic kidney disease and uncontrolled refractory gout. This can lead to increased urate burden and complications, including worsening kidney disease, cardiovascular events, and metabolic syndrome. Tune in to find out how to incorporate targeted therapies when managing uncontrolled refractory gout and improve your patients’ quality of life.
Host: John K. Botson, MD, RPh
Guest: Abdul Abdellatif, MD, FASN
Conventional oral urate-lowering therapies frequently to fail to achieve target serum uric acid (sUA) levels in patients with chronic kidney disease and uncontrolled refractory gout. This can lead to increased urate burden and complications, including worsening kidney disease, cardiovascular events, and metabolic syndrome. Tune in to find out how to incorporate targeted therapies when managing uncontrolled refractory gout and improve your patients’ quality of life.
Host: Richard Johnson, MD
Guest: Abdul Abdellatif, MD, FASN
Conventional oral urate-lowering therapies frequently to fail to achieve target serum uric acid (sUA) levels in patients with chronic kidney disease and uncontrolled refractory gout. This can lead to increased urate burden and complications, including worsening kidney disease, cardiovascular events, and metabolic syndrome. Tune in to find out how to incorporate targeted therapies when managing uncontrolled refractory gout and improve your patients’ quality of life.
Host: Richard Johnson, MD
Guest: John K. Botson, MD, RPh
Conventional oral urate-lowering therapies frequently to fail to achieve target serum uric acid (sUA) levels in patients with chronic kidney disease and uncontrolled refractory gout. This can lead to increased urate burden and complications, including worsening kidney disease, cardiovascular events, and metabolic syndrome. Tune in to find out how to incorporate targeted therapies when managing uncontrolled refractory gout and improve your patients’ quality of life.
Host: Richard Johnson, MD
Guest: John K. Botson, MD, RPh
Conventional oral urate-lowering therapies frequently to fail to achieve target serum uric acid (sUA) levels in patients with chronic kidney disease and uncontrolled refractory gout. This can lead to increased urate burden and complications, including worsening kidney disease, cardiovascular events, and metabolic syndrome. Tune in to find out how to incorporate targeted therapies when managing uncontrolled refractory gout and improve your patients’ quality of life.
Host: Richard Johnson, MD
Guest: Brittany Weber, MD, PhD
Conventional oral urate-lowering therapies frequently to fail to achieve target serum uric acid (sUA) levels in patients with chronic kidney disease and uncontrolled refractory gout. This can lead to increased urate burden and complications, including worsening kidney disease, cardiovascular events, and metabolic syndrome. Tune in to find out how to incorporate targeted therapies when managing uncontrolled refractory gout and improve your patients’ quality of life.
Host: Richard Johnson, MD
Guest: Abdul Abdellatif, MD, FASN
Conventional oral urate-lowering therapies frequently to fail to achieve target serum uric acid (sUA) levels in patients with chronic kidney disease and uncontrolled refractory gout. This can lead to increased urate burden and complications, including worsening kidney disease, cardiovascular events, and metabolic syndrome. Tune in to find out how to incorporate targeted therapies when managing uncontrolled refractory gout and improve your patients’ quality of life.
Host: Abdul Abdellatif, MD, FASN
Guest: Richard Johnson, MD
Conventional oral urate-lowering therapies frequently to fail to achieve target serum uric acid (sUA) levels in patients with chronic kidney disease and uncontrolled refractory gout. This can lead to increased urate burden and complications, including worsening kidney disease, cardiovascular events, and metabolic syndrome. Tune in to find out how to incorporate targeted therapies when managing uncontrolled refractory gout and improve your patients’ quality of life.
Host: Richard Johnson, MD
Conventional oral urate-lowering therapies frequently to fail to achieve target serum uric acid (sUA) levels in patients with chronic kidney disease and uncontrolled refractory gout. This can lead to increased urate burden and complications, including worsening kidney disease, cardiovascular events, and metabolic syndrome. Tune in to find out how to incorporate targeted therapies when managing uncontrolled refractory gout and improve your patients’ quality of life.
Host: Abdul Abdellatif, MD, FASN
Guest: Richard Johnson, MD
Conventional oral urate-lowering therapies frequently to fail to achieve target serum uric acid (sUA) levels in patients with chronic kidney disease and uncontrolled refractory gout. This can lead to increased urate burden and complications, including worsening kidney disease, cardiovascular events, and metabolic syndrome. Tune in to find out how to incorporate targeted therapies when managing uncontrolled refractory gout and improve your patients’ quality of life.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Gil Melmed, MD, MS
The inflammation biosimilar development process uses a stepwise approach with increasing certainty to generate the totality of evidence, which demonstrates the safety, purity, and potency in one or more appropriate conditions of use for which the reference product is licensed.1,2 Dive further into the role of totality of evidence in the inflammation biosimilar development and approval process with Dr. Gil Melmed, Director of Inflammatory Bowel Disease Clinical Research at the Cedars-Sinai and Professor of Medicine at Cedars-Sinai and at the David Geffen School of Medicine at University of California, Los Angeles. Dr. Melmed was compensated for participating in this program.
References:
-
US Food and Drug Administration. Quality Considerations in Demonstrating Biosimilarity of a Therapeutic Protein Product to a Reference Product Guidance for Industry. Published online April 2015. Accessed March 22, 2023. https://www.fda.gov/media/135612/download
-
US Food and Drug Administration. Scientific Considerations in Demonstrating Biosimilarity to a Reference Product Guidance for Industry. Published online April 2015. Accessed March 22, 2023. https://www.fda.gov/media/82647/download
©2023 Amgen Inc. All rights reserved. USA-CBU-81605 5/23
Host: Ethan Craig, MD, MHS
Guest: Walter Maksymowych, MB ChB, FRCP(C), FACP
Appealing treatment options for patients with SpA might be right around the corner. So why do we need further imaging modalities and what do they have to offer? To give us a peek into the future, Dr. Ethan Craig is joined by Dr. Maksymowych, Professor of Medicine at the University of Alberta and Chief Medical Officer of CARE Arthritis.
Dr. Craig and Dr. Bakewell are Novartis Consultants.
269162 03/23
Host: Jason Liebowitz, MD
Guest: Bella Mehta, MBBS, MS, MD
How can we overcome diagnostic challenges and improve awareness for Still’s disease? Dr. Jason Liebowitz is joined by Dr. Bella Mehta from Cornell Medical College to explore the diagnosis landscape for this disease.
Dr. Liebowitz and Dr. Mehta are Novartis consultants.
10/22
Host: Ethan Craig, MD, MHS
Guest: Catherine J. Bakewell, MD
Disease activity in patients with spondyloarthritis (SpA) may be challenging to assess. So when should ultrasound and MRI be used to support clinical assessment? To provide us with more insights into this topic, Dr. Ethan Craig is joined by Dr. Catherine Bakewell, Rheumatologist at Intermountain Healthcare in Salt Lake City, Utah.
Dr. Craig and Dr. Bakewell are Novartis Consultants.
269162 03/23
Host: Ethan Craig, MD, MHS
Guest: Dr. Lianne Gensler, MD
Joining Dr. Ethan Craig to explore the role of patient-reported outcomes and discuss possible obstacles in disease monitoring is Dr. Lianne Gensler from the UCSF Spondylitis Clinic at the University of California San Francisco Medical Center.
Dr. Craig and Dr. Gensler are Novartis consultants.
11/22
Host: Ethan Craig, MD, MHS
Guest: Walter Maksymowych, MB ChB, FRCP(C), FACP
Over the last 20 year or so, magnetic resonance imaging (MRI) has changed how we evaluate axial spondyloarthritis (axSpA). But with a concerning rate of false-positive MRIs in recent data, it’s time to review where the field stands now, and update what the role of MRI seems to be in the diagnosis of spondyloarthritis (SpA). Join Dr. Ethan Craig in this discussion with an expert in SpA imaging, Dr. Maksymowych, Professor of Medicine at the University of Alberta and Chief Medical Officer of CARE Arthritis.
Dr. Craig and Dr. Bakewell are Novartis Consultants.
269162 03/23
Host: Ethan Craig, MD, MHS
Guest: Sara S. McCoy, MD, PhD
While Sjögren’s disease may be challenging to diagnose, imaging developments may improve the way we detect this disease.
To learn more, Dr. Ethan Craig is joined by Dr. Sara S. McCoy, MD, PhD who runs the Sjögren’s Clinic at the University of Wisconsin.
Dr. Craig and Dr. McCoy are Novartis consultants.
247548 11/22
Host: Ethan Craig, MD, MHS
Guest: Catherine J. Bakewell, MD
Diagnosing patients with peripheral spondyloarthritis (pSpA) can often be challenging, particularly when differentiating it from other causes of inflammatory and non-inflammatory arthritis. So what is the role of ultrasound when diagnosing pSpA in patients? Join Dr. Ethan Craig as he guides this discussion with Dr. Catherine Bakewell, Rheumatologist at Intermountain Healthcare in Salt Lake City, Utah.
Dr. Craig and Dr. Bakewell are Novartis Consultants.
269162 3/23
Host: David Jayne, MD
Guest: Annette Bruchfeld, MD, PhD
ANCA-associated vasculitis (AAV) may lead to long-term organ damage and has a significant mortality risk for patients. While glucocorticoids are effective, they are associated with adverse events and impaired quality of life. Join our experts as they tackle these unmet needs in the context of the guidelines and current treatments and then dive deeper with an exploration of the potential role of complement receptor inhibition, which may be the answer to improving vasculitis.
Host: Jason Liebowitz, MD
Guest: Bella Mehta, MBBS, MS, MD
Polygenic autoinflammatory diseases can present in several ways, such as in still’s disease and systemic juvenile idiopathic arthritis. To share key insights on these diseases, Dr. Jason Liebowitz is joined by Dr. Bella Mehta from Cornell Medical College.
Dr. Liebowitz and Dr. Mehta are Novartis consultants.
10/22
Host: Ethan Craig, MD, MHS
Guest: Dr. Lianne Gensler, MD
From therapeutic options to potential outcomes, what factors should we consider when escalating treatment for patients with axial spondyloarthritis? Dr. Ethan Craig is joined by Dr. Lianne Gensler from the UCSF Spondylitis Clinic at the University of California San Francisco Medical Center to dive into these key considerations.
Dr. Craig and Dr. Gensler are Novartis consultants.
11/22
Host: Ethan Craig, MD, MHS
Guest: Sara S. McCoy, MD, PhD
Sjogren's disease can be challenging to diagnose given that it can manifest in several different ways. How can we overcome this obstacle?
To share insights on combating diagnostic challenges, Dr. Ethan Craig is joined by Dr. Sara McCoy, MD, PhD who runs the Sjögren’s Clinic at the University of Wisconsin.
Dr. Craig and Dr. McCoy are Novartis consultants.
247548 11/22
Host: Jason Liebowitz, MD
Guest: Jonathan Greer, MD
Guest: Karen McKerihan, MSN, NP-C
What do we need to know about providing infusion medication therapies to patients with rheumatologic diseases, and how should we talk to our patients about this treatment option? Joining Dr. Jason Liebowitz to explore rheumatology infusion therapy are Dr. Jonathan Greer and Ms. Karen McKerihan.
Host: Ethan Craig, MD, MHS
Guest: Dr. Lianne Gensler, MD
To figure out how to improve the detection of fibromyalgia and axial spondyloarthritis, Dr. Ethan Craig is joined by Dr. Lianne Gensler from the UCSF Spondylitis Clinic at the University of California San Francisco Medical Center.
Dr. Craig and Dr. Gensler are Novartis consultants.
11/22
Host: Ethan Craig, MD, MHS
Guest: Sara S. McCoy, MD, PhD
Because Sjogren's disease has no calculable disease activity scores or established guidelines, how do clinicians monitor disease activity?
Dr. Ethan Craig is joined by Dr. Sara S. McCoy, MD, PhD who runs the Sjögren’s Clinic at the University of Wisconsin to discuss activity monitoring for Sjögren’s disease.
Dr. Craig and Dr. McCoy are Novartis consultants.
247548 11/22
Host: Jason Liebowitz, MD
Guest: Laura Coates, MBChB, MRCP, PhD
Different domains of psoriatic arthritis can look different in each of our patients. How should that factor into our evaluation and treatment approach for this disease? Dr. Jason Liebowitz sits down with Dr. Laura Coates, an Associate Professor at Oxford University, to explore a domain-based approach to care.
Dr. Liebowitz and Dr. Coates are Novartis consultants.
Host: Jason Liebowitz, MD
Guest: Jonathan Greer, MD
Guest: Karen McKerihan, MSN, NP-C
What are some ways we can incorporate shared decision-making into the treatment of rheumatologic diseases? To answer that question, Dr. Jason Liebowitz joins Dr. Jonathan Greer and Ms. Karen McKerihan.
Host: Ethan Craig, MD, MHS
Guest: Dr. Lianne Gensler, MD
To help us understand how axial spondyloarthritis (axSpA) and inflammatory back pain (IBP) differ, Dr. Ethan Craig is joined by Dr. Lianne Gensler from the UCSF Spondylitis Clinic at the University of California San Francisco Medical Center.
Dr. Craig and Dr. Gensler are Novartis consultants.
249165 11/22
Host: Jason Liebowitz, MD
Guest: Laura Coates, MBChB, MRCP, PhD
Given that recommendations for treatment are constantly evolving, how should we adjust our therapeutic approach to provide optimal care? To answer that question, Dr. Jason Liebowitz is joined by Dr. Laura Coates, an Associate Professor at Oxford University.
Dr. Liebowitz and Dr. Coates are Novartis consultants.
245473 11/22
Host: Jason Liebowitz, MD
Guest: Bella Mehta, MBBS, MS, MD
Treatment for monogenic autoinflammatory disease can look different for our pediatric patients and our adult patients. What do we need to know? Dr. Jason Liebowitz sits down with Dr. Bella Mehta from Cornell Medical College to discuss treating these diseases.
Host: Jason Liebowitz, MD
Guest: Jonathan Greer, MD
Guest: Karen McKerihan, MSN, NP-C
With biologic therapies emerging over the past two decades, what do we need to know about them? Dr. Jason Liebowitz is joined by Dr. Jonathan Greer and Ms. Karen McKerihan to share their perspectives on these new biologics.
Host: Jason Liebowitz, MD
Guest: Sara Tedeschi, PA
As advancements in imaging continue to emerge, what does that mean for the management of gout, calcium pyrophosphate deposition, and crystalline arthritis? To answer this question, Dr. Jason Liebowitz is joined by Dr. Sara Tedsechi from Harvard Medical School.
Dr. Liebowitz and Dr. Tedeschi are Novartis consultants.
10/22
Host: Matthew S. Keller MD
Host: Monica Schwartzman, MD, MS
Getting the proper treatment for patients with psoriasis and psoriatic arthritis can be life-changing. So how can clinicians help patients find the right medication? To discuss this topic together, Dr. Matthew Keller is joined by fellow ReachMD host, Dr. Monica Schwartzman, who is also a Rheumatologist.
Host: Ethan Craig, MD, MHS
Guest: Alexis Ogdie, MD, MSCE
So how and when should we escalate or change treatments in patients with psoriatic arthritis (PsA)? To answer this question, Dr. Ethan Craig is joined by Dr. Alexis Ogdie-Beatty from the Perelman School of Medicine at the University of Pennsylvania.
Dr. Craig and Dr. Ogdie-Beatty are Novartis consultants.
221663 7/22
Host: Ethan Craig, MD, MHS
Guest: Alexis Ogdie, MD, MSCE
What are some way we can overcome the challenges that come with monitoring response to therapy for patients with psoriatic arthritis (PsA)? Dr. Ethan Craig is joined by Dr. Alexis Ogdie-Beatty from the Perelman School of Medicine at the University of Pennsylvania to discuss the importance of monitoring and share strategies.
Dr. Craig and Dr. Ogdie-Beatty are Novartis consultants.
221663 7/22
Host: Ethan Craig, MD, MHS
Guest: Alexis Ogdie, MD, MSCE
What are some way we can overcome the challenges that come with monitoring response to therapy for patients with psoriatic arthritis (PsA)? Dr. Ethan Craig is joined by Dr. Alexis Ogdie-Beatty from the Perelman School of Medicine at the University of Pennsylvania to discuss the importance of monitoring and share strategies.
Dr. Craig and Dr. Ogdie-Beatty are Novartis consultants.
221663 7/22
Host: Jason Liebowitz, MD
Guest: Sara Tedeschi, PA
What do we need to know about the epidemiology and pathogenesis of calcium pyrophosphate deposition? Dr. Jason Liebowitz is joined by Dr. Sara Tedeschi from Harvard Medical School to share key insights on CPPD.
Dr. Liebowitz and Dr. Tedeschi are Novartis consultants
10/22 236268
Host: Jason Liebowitz, MD
Guest: Sara Tedeschi, PA
What do we need to know about the epidemiology and pathogenesis of calcium pyrophosphate deposition? Dr. Jason Liebowitz is joined by Dr. Sara Tedeschi from Harvard Medical School to share key insights on CPPD.
Dr. Liebowitz and Dr. Tedeschi are Novartis consultants
10/22 236268
Host: Ethan Craig, MD, MHS
Guest: Alexis Ogdie, MD, MSCE
For patients with oligoarticular arthritis, how can imaging features help us distinguish psoriatic arthritis from other inflammatory processes? Joining Dr. Ethan Craig to answer that question is Dr. Alexis Ogdie-Beatty from the Perelman School of Medicine at the University of Pennsylvania.
Dr. Craig and Dr. Ogdie-Beatty are Novartis consultants.
221663 7/22
Host: Ethan Craig, MD, MHS
Guest: Alexis Ogdie, MD, MSCE
For patients with oligoarticular arthritis, how can imaging features help us distinguish psoriatic arthritis from other inflammatory processes? Joining Dr. Ethan Craig to answer that question is Dr. Alexis Ogdie-Beatty from the Perelman School of Medicine at the University of Pennsylvania.
Dr. Craig and Dr. Ogdie-Beatty are Novartis consultants.
221663 7/22
Host: Anisha Dua, MD, MPH
Guest: Michael Putman, MD, MSci
What does the therapeutic landscape look like for patients with giant cell arthritis (GCA)? Joining Dr. Anisha Dua to highlight the need for more targeted therapies is Dr. Mike Putman from the Medical College of Wisconsin.
Dr. Dua and Dr. Putman are Novartis consultants.
199849 6/22
Host: Anisha Dua, MD, MPH
Guest: Michael Putman, MD, MSci
What does the therapeutic landscape look like for patients with giant cell arthritis (GCA)? Joining Dr. Anisha Dua to highlight the need for more targeted therapies is Dr. Mike Putman from the Medical College of Wisconsin.
Dr. Dua and Dr. Putman are Novartis consultants.
199849 6/22
Host: Ethan Craig, MD, MHS
Guest: Alexis Ogdie-Beatty, MD, MSCE
How does preclinical psoriatic arthritis (PsA) progress into chronic PsA? To dive into this path of progression, Dr. Ethan Craig is joined by Dr. Alexis Ogdie-Beatty from the Perelman School of Medicine at the University of Pennsylvania.
Dr. Craig and Dr. Ogdie-Beatty are Novartis consultants.
221663 7/22
Host: Ethan Craig, MD, MHS
Guest: Alexis Ogdie-Beatty, MD, MSCE
How does preclinical psoriatic arthritis (PsA) progress into chronic PsA? To dive into this path of progression, Dr. Ethan Craig is joined by Dr. Alexis Ogdie-Beatty from the Perelman School of Medicine at the University of Pennsylvania.
Dr. Craig and Dr. Ogdie-Beatty are Novartis consultants.
221663 7/22
Host: Anisha Dua, MD, MPH
Guest: Michael Putman, MD, MSci
What are some imaging factors we should consider when monitoring giant cell arthritis (GCA) and the medication prescribed for it? Dr. Anisha Dua is joined by Dr. Mike Putman to explore these factors.
Dr. Dua and Dr. Putman are Novartis consultants.
199849 6/22
Host: Anisha Dua, MD, MPH
Guest: Michael Putman, MD, MSci
What are some imaging factors we should consider when monitoring giant cell arthritis (GCA) and the medication prescribed for it? Dr. Anisha Dua is joined by Dr. Mike Putman to explore these factors.
Dr. Dua and Dr. Putman are Novartis consultants.
199849 6/22
Host: Anisha Dua, MD, MPH
Guest: Elaine Husni, MD, MPH
The risk of developing cancer may be higher in patients with spondyloarthritis, or SpA for short.1-6 What do we need to know about the risk of cancer, as well as other malignancies in these patients? Dr. Anisha Dua joins Dr. Elaine Husni from the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University to explore malignancies in SpA.
Dr. Dua and Dr. Husni are Novartis consultants.
- Deng C, Li W, Fei Y, Li Y, Zhang F. Risk of malignancy in ankylosing spondylitis: a systematic review and meta-analysis. Sci Rep. 2016;6:1-6.
- Gross R, Schwartzman-Morris J, Krathen M, et al. A comparison of malignancy incidence among psoriatic and rheumatoid arthritis patients in a large US cohort. Arthritis Rheumatol. 2014;66(6):1472-1481.
- Chiesa Fuxench ZC, Shin DB, Ogdie Beatty A, Gelfand JM. The risk of cancer in patients with psoriasis: a population-based cohort study in the health improvement network. JAMA Dermatology. 2016;152(3):282-290.
- Moon H-I, Chang H-J, Kim J-E, Ko H-Y, Ann S-H, Min C-K. The association between multiple myeloma and ankylosing spondylitis: a report of two cases. Korean J Hematol. 2009;44(3):182-187.
- Chang CC, Chang CW, Nguyen PAA, et al. Ankylosing spondylitis and the risk of cancer. Oncol Lett. 2017;14(2):1315-1322.
- Karmacharya P, Shahukhal …
Host: Anisha Dua, MD, MPH
Guest: Michael Putman, MD, MSci
With several guidelines available—what imaging considerations should we keep in mind when it comes to diagnosing giant cell arthritis (GCA)? Joining Dr. Anisha Dua to walk us through the guidelines and make recommendations is Dr. Mike Putman.
Dr. Dua and Dr. Putman are Novartis consultants.
199849 6/22
Host: Anisha Dua, MD, MPH
Guest: Michael Putman, MD, MSci
With several guidelines available—what imaging considerations should we keep in mind when it comes to diagnosing giant cell arthritis (GCA)? Joining Dr. Anisha Dua to walk us through the guidelines and make recommendations is Dr. Mike Putman.
Dr. Dua and Dr. Putman are Novartis consultants.
199849 6/22
Host: Anisha Dua, MD, MPH
Guest: Elaine Husni, MD, MPH
The estimates of prevalence of depression across the axial spondyloarthritis spectrum ranges from 11% to 64%. How we can help these patients manage their mental health? To find out more, Dr. Anisha Dua is joined by Dr. Elaine Husni from the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University.
Dr. Dua and Dr. Husni are Novartis consultants.
Zhao SS, Thong D, Miller N, et al. The prevalence of depression in axial spondyloarthritis and its association with disease activity: a systematic review and meta-analysis. Arthritis Res Ther. 2018;20(1):1-9.
196466 6/22
Host: Anisha Dua, MD, MPH
Guest: Elaine Husni, MD, MPH
The estimates of prevalence of depression across the axial spondyloarthritis spectrum ranges from 11% to 64%. How we can help these patients manage their mental health? To find out more, Dr. Anisha Dua is joined by Dr. Elaine Husni from the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University.
Dr. Dua and Dr. Husni are Novartis consultants.
Zhao SS, Thong D, Miller N, et al. The prevalence of depression in axial spondyloarthritis and its association with disease activity: a systematic review and meta-analysis. Arthritis Res Ther. 2018;20(1):1-9.
196466 6/22
Host: Anisha Dua, MD, MPH
Guest: Grace C Wright, MD, PhD
Guest: Irene Blanco, MD, MS
How can we improve diversity in the rheumatology workforce? Joining Dr. Anisha Dua to explore underrepresentation in the workforce are Dr. Grace Wright and Dr. Irene Blanco.
Drs. Dua, Blanco, and Wright are Novartis consultants.
194889 4/22
Host: Anisha Dua, MD, MPH
Guest: Grace C Wright, MD, PhD
Guest: Irene Blanco, MD, MS
How can we improve diversity in the rheumatology workforce? Joining Dr. Anisha Dua to explore underrepresentation in the workforce are Dr. Grace Wright and Dr. Irene Blanco.
Drs. Dua, Blanco, and Wright are Novartis consultants.
194889 4/22
Guest: Elaine Husni, MD, MPH
Host: Anisha Dua, MD, MPH
Physical activity has shown to have many benefits for patients with spondyloarthritis, or SpA for short. What kind of role does it have in the treatment of these patients? To answer this question, Dr. Anisha Dua is joined by Dr. Elaine Husni from the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University
Dr. Dua and Dr. Husni are Novartis consultants.
O’Dwyer T, O’Shea F, Wilson F. Physical activity in spondyloarthritis: a systematic review. Rheumatol Int. 2015;35(3):393-404.
196466 6/22
Host: Anisha Dua, MD, MPH
Guest: Grace C Wright, MD, PhD
Guest: Irene Blanco, MD, MS
What are some of the social determinants that can impact patient outcomes? Joining Dr. Anisha Dua to share strategies to improve these inequities are Dr. Grace Wright and Dr. Irene Blanco.
Drs. Dua, Blanco, and Wright are Novartis consultants.
194889 4/22
Host: Jason Liebowitz, MD
Guest: Michael Putman, MD, MSci
Shared treatment decisions can help guide patient care—but how can we implement them in our practice? Drs. Jason Liebowitz and Michael Putman share tips and strategies to implement shared decision-making (SDM) in rheumatology.
Dr. Liebowitz and Dr. Putman are Novartis consultants.
194889 4/22
Host: Anisha Dua, MD, MPH
Guest: Elaine Husni, MD, MPH
Patients with spondyloarthritis, or SpA for short, can be at an increased cardiovascular risk.1,2 To learn how we can better understand and manage this risk, Dr. Anisha Dua is joined by Dr. Elaine Husni from the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University.
Dr. Dua and Dr. Husni are Novartis consultants.
- Zhao SS, Robertson S, Reich T, Harrison NL, Moots RJ, Goodson NJ. Prevalence and impact of comorbidities in axial spondyloarthritis: systematic review and meta-analysis. Rheumatol (United Kingdom). 2020;59:iv47-iv57.
- Papagoras C, Markatseli TE, Saougou I, et al. Cardiovascular risk profile in patients with spondyloarthritis. Jt Bone Spine. 2014;81(1):57-63.
196466 6/22
Host: Jason Liebowitz, MD
Guest: Michael Putman, MD, MSci
Social media is often used as a tool to network and connect to people around the world—but can rheumatologists use it to connect with their patients? Drs. Jason Liebowitz and Michael Putman share how rheumatologists can use it to improve care.
Dr. Liebowitz and Dr. Putman are Novartis consultants.
194889 4/22
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Nick Kusnezov, MD
Can you balance locum tenens with a full-time career? To answer that question, Dr. Charles Turck is joined by board-certified orthopedic surgeon, Dr. Nicholas Kusnezov, to walk us through his journey from joining the military to locum tenens.
Host: Jennifer Caudle, DO
Guest: Roni Devlin, MD
As rates of burnout continue to rise in the healthcare community, how can help our female physicians combat it? Dr. Jennifer Caudle joins Infectious Disease Specialist, Dr. Roni Devlin, to discuss how we can prevent burnout for female physicians.
Host: Anisha Dua, MD, MPH
Guest: Grace C Wright, MD, PhD
Guest: Irene Blanco, MD, MS
What are some ways we can improve diversity in our workforce? Joining Dr. Anisha Dua to share how clinicians can make the workforce more inclusive are Dr. Grace Wright and Dr. Irene Blanco.
Drs. Dua, Blanco, and Wright are Novartis consultants.
194889 4/22
Host: Jason Liebowitz, MD
Guest: Michael Putman, MD, MSci
As evidence-based medicine (EBM) continues to evolve, what do rheumatologists need to know to keep up? Drs. Jason Liebowitz and Michael Putman dive into EBM and its role in the field of rheumatology.
Dr. Liebowitz and Dr. Putman are Novartis consultants.
194889 4/22
Host: Anisha Dua, MD, MPH
Guest: Grace C Wright, MD, PhD
Guest: Irene Blanco, MD, MS
How can we improve representation in rheumatology clinical trials? To share strategies, Dr. Anisha Dua joins Dr. Grace Wright and Dr. Irene Blanco to discuss diversity in clinical trials.
Drs. Dua, Blanco, and Wright are Novartis consultants.
194889 4/22
Host: Jason Liebowitz, MD
Guest: Michael Putman, MD, MSci
What do we need to know about the latest technologies changing the field of rheumatology? Drs. Jason Liebowitz and Michael Putman share the latest innovations.
Dr. Liebowitz and Dr. Putman are Novartis consultants.
192544 4/22
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Trevor Cabrera, MD
What’s it like becoming a locum tenens physician right out of residency? Dr. Charles Turck joins Dr. Trevor Cabrera, a Board-Certified pediatrician who trained in Houston, Texas, to share his firsthand experience and offer advice for residents.
Host: Paul P. Doghramji, MD, FAAFP
Guest: Samantha Conroy, MD
Locum tenens can improve quality of care around the globe—especially in remote and underserved communities. To share how, Dr. Paul Doghramji joins Dr. Samantha Conroy, a family practice obstetrician to share her experiences working as a locum tenens obstetrician in underserved communities.
Host: Jennifer Caudle, DO
Guest: Maurice G. Sholas, MD, PhD
After years of serving the New Orleans community, one physician decided to pursue locum tenens work. Dr. Jennifer Caudle joins Dr. Maurice Sholas, a pediatric physical rehabilitation physician, to share his experiences with locum tenens and in New Orleans.
Host: Jennifer Caudle, DO
Guest: April W. Armstrong, MD, MPH
Guest: Allan Gibofsky, MD, JD, MACR, FACP, FCLM
There's good news for patients and clinicians dealing with the challenges of psoriasis or psoriatic arthritis (PsA). Novel and emerging therapies exist that can help improve symptoms, and slow or prevent disease progression. In this fast-paced, clinical discussion, you'll hear from two leading experts who will share recent evidence and highlights from the American Academy of Dermatology (AAD) Annual Meeting that support using novel biologic and targeted synthetic agents for psoriasis and PsA. As part of the discussion, they also examine a patient case illustrating how you can optimize treatment plans, integrate the latest guideline recommendations in your practice, and encourage shared decision making with your patients.
Host: Jennifer Caudle, DO
Guest: April W. Armstrong, MD, MPH
Guest: Allan Gibofsky, MD, JD, MACR, FACP, FCLM
There's good news for patients and clinicians dealing with the challenges of psoriasis or psoriatic arthritis (PsA). Novel and emerging therapies exist that can help improve symptoms, and slow or prevent disease progression. In this fast-paced, clinical discussion, you'll hear from two leading experts who will share recent evidence and highlights from the American Academy of Dermatology (AAD) Annual Meeting that support using novel biologic and targeted synthetic agents for psoriasis and PsA. As part of the discussion, they also examine a patient case illustrating how you can optimize treatment plans, integrate the latest guideline recommendations in your practice, and encourage shared decision making with your patients.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Carlos Jesus Acuña-Villaorduña, MD
What are some of the immunologic mechanisms that alter our ability to fight off a mycobacterium tuberculosis infection—and how does this affect our immunocompromised patients? To answer this question, Dr. Charles Turck meets with Dr. Carlos Acuña-Villaorduña from the Boston University School of Medicine to discuss new insights on TB infection and immunosuppression.
Host: Neilanjan Nandi, MD
Guest: Monica Schwartzman, MD, MS
It's estimated that 50 percent of patients with IBD experience arthralgia, with the most common form being peripheral arthritis. What screening strategies are available to help us identify those patients with peripheral discomforts? Tune in to hear multidisciplinary perspectives on peripheral arthritis in IBD from gastroenterologist Dr. Neil Nandi and rheumatologist Dr. Monica Schwartzman.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Gates B. Colbert, MD, FASN
Guest: Robin Dore, MD
When managing patients with lupus nephritis, it’s imperative that rheumatologists and nephrologists work together to coordinate care. Unfortunately, several challenges can keep us from putting care coordination strategies into practice, so how can we overcome those challenges and incorporate shared decision-making into our clinical approach to lupus nephritis? Joining Dr. Charles Turck to share their perspectives are rheumatologist Dr. Robin Dore and nephrologist Dr. Gates Colbert.
Host: William Mencia, MD, FACEHP, CHCP
Guest: Andrew F. Alexis, MD, MPH
There is often a delay in the diagnosis of psoriasis and/or psoriatic arthritis for people with skin of color. Among the multiple factors that cause this disparity are a low index of suspicion for such a diagnosis in skin of color and a lack of familiarity with the morphology of these conditions in richly pigmented skin. Join Drs. William Mencia and Andrew Alexis as they address pathways to overcoming these systemic and experiential healthcare barriers.
Host: Sergio Schwartzman, MD
Guest: April W. Armstrong, MD, MPH
Guest: Philip J. Mease, MD, MACR
Integrating routine assessments of psoriatic arthritis (PsA)-related structural progression has proven challenging in clinical practice. Join Drs. Sergio Schwartzman, Philip Mease, and April Armstrong as they discuss evidence that frequent monitoring of PsA structural progression permits earlier intervention with effective therapies as well as provides indications for when to switch to another class of agent. They also address which therapeutic agents have been shown to impact PsA structural progression in clinical trials and provide insight into how best to incorporate collaborative treatment strategies across disciplines. These practices are likely to improve outcomes for patients with PsA, so be sure to stay informed.
Host: Neilanjan Nandi, MD
Guest: Monica Schwartzman, MD, MS
It's currently estimated that 50 percent of IBD patients experience some form of joint stiffness, otherwise known as arthralgia. With so many patients being affected, how can you determine if it’s inflammatory or noninflammatory arthralgia and treat it appropriately? To find out, Dr. Neil Nandi speaks with Dr. Monica Schwartzman, assistant attending physician at the Hospital for Special Surgery and Clinical Instructor of Medicine at Weill Cornell Medical College. Together, they’ll discuss the screening tools gastroenterologists can use to differentiate the types of arthralgia in their patients as well as key management approaches.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Jeffrey D. Cirillo, PhD
How prevalent is tuberculosis in long-term care facilities? To better understand this, Dr. Charles Turck meets with Dr. Jeffrey Cirillo to examine screening and testing strategies to better monitor TB risk, specifically for high-risk patient populations.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Laila Woc-Colburn, MD, DTM&H, FACP, FIDSA
What are some ways we can better care for our patients prior to starting biologic therapy? Dr. Charles Turck joins Dr. Laila Woc-Colburn from the Emory University School of Medicine to discuss ways to improve safety for patients with tuberculosis.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Sandy Marks
Guest: Kim Horvath, JD
Guest: Kyle Thomson, JD
With telehealth services expanding during the COVID-19 pandemic, has our access to them changed? To better understand this, Dr. Charles Turck meets with Sandy Marks, Kim Horvath, and Kyle Thomson from the AMA to explore what’s been done to provide Medicare coverage during a public health emergency and what’s on the horizon for telehealth access.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Emily Carroll, JD, MSW
The No Surprises Act aims to protect consumers from surprise medical bills. But how exactly does it go about doing that, and what’s the current status of its implementation? Joining Dr. Charles Turck to share progress and challenges associated with the No Surprises Act is Ms. Emily Carroll, a senior legislative attorney for the American Medical Association's Advocacy Resource Center.
Host: Jennifer Caudle, DO
Guest: Sarah Ali, MD
From working in a big city to taking on an assignment in a small mountain village, Dr. Sarah Ali from the Ventura County Medical Center joins Dr. Jennifer Caudle to talk about her adventures abroad with locum tenens and share key lessons she learned along the way.
Host: Neilanjan Nandi, MD, FACP
Guest: Sergio Schwartzman, MD
Inflammatory bowel disease (IBD) has long been associated with the development of arthritis, which can be detected in up to 30 percent of IBD patients. So how can gastroenterologists and rheumatologists work together to detect and manage IBD-associated arthritis? To find out, Dr. Neil Nandi speaks with rheumatologist Dr. Sergio Schwartzman about IBD-associated arthritis.
Guest: Randy Cron, MD, PhD
Dr. Randy Cron, Professor of Pediatrics and Medicine at the University of Alabama at Birmingham and the Director of the Division of Pediatric Rheumatology at Children’s of Alabama, shares highlights from his session on “Rheumatology Complications of Emerging Viral Infections and SARS-CoV-2” from the 2021 American College of Rheumatology Convergence.
Host: Laura Cappelli, MD, MHS,MS
What does the future of rheumatology look like around the globe? Here to give a quick overview of her presentation at the 2021 American College of Rheumatology (ACR) Convergence is Dr. Laura Cappelli, Assistant Professor of Medicine at the Johns Hopkins University School of Medicine Division of Rheumatology and a faculty member of the Johns Hopkins Arthritis Center.
Host: Paul P. Doghramji, MD, FAAFP
Guest: Mojgan Saber, MD
Can Locum Tenens be an option for healthcare professionals just completing their residency? Dr. Paul Doghramji is joined by Dr. Mojgan Saber to share her own experience as well as tips and tricks for residents looking at Locum Tenens right after residency.
Host: Charles P. Vega, MD
Guest: Sateria Venable
Regional healthcare disparities are biases that are based on where people live. Are your patients’ treatment options being impacted and limited by their geographical location? Join us as our two experts discuss how to support broader policy issues and highlight the importance of diagnostic algorithms that have been developed with diverse input. These steps may be of value in your clinical practice to ensure all patients have equal access to care regardless of their epidemiologic, socioeconomic, or insurance circumstances.
Host: Jennifer Caudle, DO
Guest: Stephen Hanauer, MD
Even though biosimilars serve as a much-needed treatment option for patients in several fields of medicine, gastroenterologists have been reluctant to adopt them. Joining Dr. Jennifer Caudle to explore why this might be and the evolving role of biosimilars in anti-inflammatory care for GI patients is Dr. Stephen Hanauer, Professor of Medicine at the Northwestern University Feinberg School of Medicine in Chicago, Illinois.
USA-CBU-81030
Guest: John J. Ryan MD, MB, BCh, BAO, MRCPI, FACC, FAHA
John Ryan, MD discusses screening protocols, diagnostic and treatment algorithms, clinical trial evidence, and the vital role of multidisciplinary teams for the management of patients with CTD-PAH in this four-chapter series.
Host: Matt Birnholz, MD
Guest: Alexis Ogdie, MD, MSCE
Axial psoriatic arthritis (axPsA) is a challenging clinical entity to characterize, with a prevalence ranging anywhere between 12.5% and 78% of psoriatic arthritis patients because of varied definitions and inclusion criteria. To learn more about how we can better define and diagnose axPsA, Dr. Matt Birnholz is joined by Dr. Alexis Ogdie, Associate Professor of Medicine and Epidemiology at the University of Pennsylvania.
4/21 M-XAT-1400586
Host: Christopher T. Ritchlin, MD, MPH
Guest: Petros Efthimiou, MD, FACR
Guest: Olga Petryna, MD, FACR
Is it time to connect the dots between systemic juvenile idiopathic arthritis (SJIA) and adult-onset Still’s disease (AOSD)? There is a growing recognition that SJIA and AOSD represent the same disease continuum with different ages of onset.1 Both conditions are rare autoinflammatory disorders of unknown etiology.1 In addition to Still’s disease rarity, patients present with varying symptoms and are diagnosed by exclusion of other diseases, which may result in a long time to proper care.2,3 A delay in diagnosis and failure to control disease activity can lead to severe and life-threatening complications.4 A multidisciplinary team effort and greater disease awareness are necessary to help expedite the therapeutic journey of patients with Still’s disease.5
Listen in to a discussion panel moderated by Christopher T. Ritchlin, MD with Petros Efthimiou, MD and Olga Petryna, MD as they have a conversation on the concept of the continuum of Still’s disease, its burden, and the patient journey.
This presentation is sponsored by Novartis Medical Affairs and all speakers have been compensated for their time.
References
- Vastert SJ, Jamilloux Y, Quartier P, et al. Anakinra in children and adults with Still’s disease. Rheumatology. 2019;58(suppl 6):vi9-vi22. doi:10.1093/rheumatology/kez350
- Efthimiou P. Diagnosis and management of adult onset …
Host: Joshua Sharfstein, MD
Host: Stephanie Desmon
Guest: Maximilian Konig, MD
Guest: Chetan Bettegowda, MD, PhD
For the subset of people who become critically ill from the novel coronavirus, cytokine storms could be to blame. This severe inflammatory disease happens when the immune system goes haywire in response to a novel threat. Rheumatology fellow Dr. Max Konig and neurosurgeon Dr. Chetan Bettegowda talk with Stephanie Desmon about the vital role of cytokine in immune responses, how to identify who might be at risk, and how research is looking into stopping the storms before they start.
Published April 28, 2020
Host: Michael Greenberg, MD
Guest: Madelaine A. Feldman, MD, FACR
A multidisciplinary approach between dermatologists and rheumatologists is required for treating and caring for patients with psoriatic arthritis (PsA). So how should these two specialists work together to achieve the best outcome for their patients? What challenges do they each face, and how can they overcome them?
Dr. Michael Greenberg, dermatologist from the Illinois Dermatology Institute, and Dr. Madelaine Feldman, Clinical Associate Professor of Medicine at Tulane University School of Medicine and practicing rheumatologist, come together to provide their perspectives from their careers on this topic.
Beyond Skin Deep: Impacts of Psoriatic Arthritis is sponsored by Lilly. Content for this non-certified educational series is produced and controlled by ReachMD. This series is intended for health care professionals only.
Guest: Alexis Ogdie, MD, MSCE
Along with the management of psoriatic arthritis, many patients also struggle with multiple, underlying comorbidities, increasing the complexity of the disease. In a review of the associated comorbidities that can emerge from PsA, Dr. Alexis Ogdie brings another aspect to the forefront: the all-too-often underrecognized comorbidities and risk factors.
Beyond Skin Deep: Impacts of Psoriatic Arthritis is sponsored by Lilly. Content for this non-certified educational series is produced and controlled by ReachMD. This series is intended for health care professionals only.
Host: Matt Birnholz, MD
Guest: Alexis Ogdie, MD, MSCE
Due to the complexity of psoriatic arthritis, working with a team of physicians helps ensure all facets of this disease are being addressed, but how can you sustain a partnership? Dr. Alexis Ogdie, Assistant Professor at the University of Pennsylvania, expresses the value of multidisciplinary teams in her practice to promote a patient-centered approach.
Beyond Skin Deep: Impacts of Psoriatic Arthritis is sponsored by Lilly. Content for this non-certified educational series is produced and controlled by ReachMD. This series is intended for health care professionals only.
Guest: Adrienne Rencic, MD, PhD
Many psoriatic arthritis patients struggle in determining the proper physician they should seek for treatment and care management. Since dermatologists are usually consulted first due to skin manifestations, it’s crucial that they are able to recognize the symptoms of PsA and know when to refer the patient to another specialist. Dr. Adrienne Rencic, a dermatologist in Glen Mills, PA, emphasizes the power of communication to achieve good coordination of care.
Beyond Skin Deep: Impacts of Psoriatic Arthritis is sponsored by Lilly. Content for this a non-certified educational series is produced and controlled by ReachMD. This series is intended for health care professionals only.
Host: Jennifer Caudle, DO
Guest: Marina Magrey, MD
While there is no cure for psoriatic arthritis, there have been great strides in treatment options to minimize disease symptoms. Joining Dr. Jennifer Caudle to share her approach to treatment is Dr. Marina Magrey. Their conversation explores the current landscape of therapeutic targets and what might be on the horizon for psoriatic arthritis patients and their physicians.
Beyond Skin Deep: Impacts of Psoriatic Arthritis is sponsored by Lilly. Content for this a non-certified educational series is produced and controlled by ReachMD. This series is intended for health care professionals only.
Host: Madelaine A. Feldman, MD, FACR
Join Dr. Maddie Feldman as she gains exclusive insights from rheumatologist Dr. Jerry Pounds, who attended a lecture given by lupus guru Dr. Michelle Petri at this year’s Congress of Clinical Rheumatology’s Annual Meeting in Destin, Florida.
Guest: Robin K. Dore, MD
Dr. Robin Dore joins us to answer some of the most frequently asked questions about PASI, like what these scores are, how they’re used, and how they affect the outcomes of your psoriatic arthritis patients.
Beyond Skin Deep: Impacts of Psoriatic Arthritis is sponsored by Lilly. Content for this a non-certified educational series is produced and controlled by ReachMD. This series is intended for health care professionals only.
Guest: Elizabeth Volkmann, MD, MS
When assessing for low or minimal disease activity in psoriatic arthritis patients, there are three things you need to consider: patient-centered criteria, physical examination findings, and laboratory measures. Explore how you can use this combination of outcome measurements in your practice with rheumatologist and clinical researcher at the Ronald Reagan Medical Center at UCLA, Dr. Elizabeth Volkmann.
Beyond Skin Deep: Impacts of Psoriatic Arthritis is sponsored by Lilly. Content for this a non-certified educational series is produced and controlled by ReachMD. This series is intended for health care professionals only.
Host: John J. Russell, MD
Guest: Paul M. O'Connor
Sodium bicarbonate (more commonly known as baking soda) has been used as a raising agent when baking delicious sweets for years. But as new research suggests, taking a daily dose of baking soda could also be used as a therapeutic agent. Tune in as Dr. John Russell speaks with Dr. Paul O'Connor, Renal Physiologist at the Medical College of Georgia in Augusta, about his recent investigation into how this common household product could treat autoimmune diseases such as rheumatoid arthritis.
Guest: J. Eugene Huffstutter, MD
Care coordination is key in ensuring that your psoriatic arthritis (PsA) patients maintain control of their disease, but it’s not always easy. To help you overcome this common challenge, Dr. Joseph Huffstutter, Assistant Clinical Professor at University of Tennessee College of Medicine at Chattanooga, shares his perspective on how you can coordinate your PsA patients’ care with not only their healthcare team but also their family members.
Beyond Skin Deep: Impacts of Psoriatic Arthritis is sponsored by Lilly. Content for this a non-certified educational series is produced and controlled by ReachMD. This series is intended for health care professionals only.
Host: Jennifer Caudle, DO
Guest: Anne Negrin, MD
Since eye issues are becoming increasingly common in patients with rheumatological conditions, it’s now more vital than ever that physicians are aware of their common symptoms. Joining Dr. Jennifer Caudle is Dr. Anne Negrin, an ophthalmologist in New York, to break down these symptoms and to focus on rheumatological concerns that ophthalmologists see in practice.
Host: Jennifer Caudle, DO
Guest: Ashira Blazer, MD
Did you know that African Americans are three times as likely to be diagnosed with lupus than other demographic groups? To make matters worse, being diagnosed with lupus doubles their risk of kidney disease, stroke, and heart attacks.
To address this growing health threat among African Americans, Dr. Jennifer Caudle is joined by Dr. Ashira Blazer, Instructor in the Department of Medicine and Rheumatologist at NYU Langone Health, to discuss diagnosis, comorbidities, and various treatment options for your lupus patients.
Correction Note: Dr. Blazer has updated that in the U.S., variation homozygosity for APOL1 is present in 13% of the African American population.
Guest: Robert A. Baldor, MD
Guest: Chadwick R. Johr, MD
This innovative, 45-minute, case-based CME activity features two prominent faculty covering important, timely issues and data related to the detection of autoimmune (AI) disorders. Using case studies, the faculty will explore diagnosis and management strategies to maximize patient care. In addition to the analysis of AI cases, key topics will be covered, including:
- Evaluation for suspected RA
- Combination serological assessment
- 14-3-3eta as a marker for joint damage
- Autoantibodies in SLE diagnosis and classification
- ANA IFA and subserologies
- Diagnosis of RA, Sjögren’s, Lupus, and Systemic Sclerosis
Guest: Robert A. Baldor, MD
Guest: Chadwick R. Johr, MD
This innovative, 30-minute, online activity features a Video Expert Dialogue with two prominent faculty covering important, timely issues and data related to the detection of autoimmune (AI) disorders. The emphasis is on the unique role primary care providers play in diagnosing and managing AI and maximizing patient care. Topics include:
- Overview of connective tissue diseases and ANA testing
- ANA IFA and ELISA
- New tests
- Subserologies with IFA
- Choosing wisely about ANA testing
- Diagnosis of RA, Sjögren’s, Lupus, and Systemic Sclerosis
- Titer Information
- Negative ANA testing
- When to refer
We’ll be discussing autoantibody testing for autoimmune diseases, or more precisely, connective tissue diseases. Our purpose here is to discuss how autoantibody testing, such as the ANA, may be used in the primary care setting to diagnose these disorders. Using the ANA test combined with a good medical exam and a good history, along with signs and symptoms of connective tissue diseases, will help to achieve greater benefits in diagnosing and treating patients.
Host: Barnett Mennen, MD
Guest: Comron Saifi, MD
Spinal deformity places strain on the vertebrae and supporting muscles, tendons, ligaments, and tissues supporting the spinal column. The treatment and management of this condition becomes centrally important to maintain patient quality of life through functional mobility and activity levels.
Host, Dr. Barry Mennen and Dr. Comron Saifi discuss the leading assessment and treatment options for spinal deformity. Dr. Saifi is an Assistant Professor of Orthopaedic Surgery in the Division of Spine Surgery at the Perelman School of Medicine at the University of Pennsylvania.
Guest: Leonard H. Calabrese, DO
Guest: John R. Tesser, MD
This activity provides patient and practice-specific biosimilars content for clinicians in rheumatology practice.
Host: Michael Greenberg, MD
Guest: Michele Meltzer, MD
Rheumatology services are limited or non-existent in many parts of sub-Saharan Africa. Basic diagnostic tests, biological agents, and treatments are either unavailable or not affordable for the majority of people living in that area.
This shortage results in patients not having the benefit of early diagnosis and management of relatively cheap and cost-effective therapies. Instead, they present at advanced stages of disease with otherwise preventable morbidity.
Host Michael Greenberg chats with Dr. Michele Meltzer, Associate Professor at Jefferson University Hospitals in Philadelphia and President of the non-profit organization, Rheumatology for All, about providing medical training and care for countries with limited or non-existent rheumatology services.
Host: Brian P. McDonough, MD, FAAFP
With more than 100 different disorders, rheumatic diseases comprise one of the most prevalent disease groups in the industrialized world. In fact, a third of the population will be affected by a rheumatic disease at some point during their lifetimes.
Host Dr. Brian McDonough sits down with Dr. Carol Langford, Chair of the Committee of Education at the American College of Rheumatology, about the diagnostic and treatment challenges of rheumatic diseases.
Host: Kathy King, RDN
Lyme disease is one of the most puzzling illnesses on the planet. Anyone who has suffered from its debilitating symptoms knows the frustrations of trying to find a cure.
Joining host Kathy King is Dr. Bill Rawls, physician and author of the book Unlocking Lyme: Myths, Truths and Practical Solutions for Chronic Lyme Disease. Dr. Rawls, who overcame Lyme disease himself, gives a comprehensive, practical review of clinical approaches.
Host: Renée Simone Yolanda Allen, MD, MHSc., FACOG
Guest: Xena Whittier, MD
Rheumatic diseases don't discriminate across race or gender; however, significant health disparities continue to exist for patients suffering from these diseases.
Dr. Renée Simone Yolanda Allen speaks with Dr. Xena Whittier, practicing rheumatologist with WellStar Rheumatology Associates in Marietta, GA, about closing the gap in health disparities for rheumatology patients across genders, ethnicities, and socioeconomic statuses.
Host: Jennifer Caudle, DO
Guest: Michael Lewiecki, MD, FACP, FACE
With an incidence rate of more than 750,000 per year, vertebral fractures contribute significantly to morbidity and mortality rates in osteoporosis patients, particularly those who have sustained a VCF in the past. In this new segment, we will hear from Dr. Michael Lewiecki, as he examines this debilitating issue. Dr. Lewiecki is the Director of the New Mexico Clinical Research and Osteoporosis Center; and, Clinical Assistant Professor of Medicine at UNM School of Medicine in Albuquerque, New Mexico.
Host: Shira Johnson, MD
Guest: Meryl S. LeBoff, MD
Osteoporosis is a major public health threat for an estimated 54 million Americans 50 years of age and older. In the U.S. today, 10.2 million individuals are estimated to already have the disease and 43.4 million more are estimated to have low bone mass, placing them at increased risk for osteoporosis and fractures. Because bone density tends to decline with age, the problem of osteoporosis has reached epidemic proportions with the rapidly aging population. It is estimated that by 2020 over 61 million Americans will have osteoporosis or low bone mass. Join host Dr. Shira Johnson welcomes Dr. Meryl LeBoff, Endocrinologist; Chief of the Calcium and Bone Section at Brigham Women's Hospital in Boston, Massachusetts; and, trustee of the National Osteoporosis Foundation.
About NOF & Fracture Liaison Service (FLS)
NOF has adopted the 20/20 Vision of the National Bone Health Alliance (NBHA), of which NOF is a founding member. The goal is to reduce bone breaks by 20% by the year 2020.
Approximately 2 million fractures are caused by osteoporosis each year. Compliance around osteoporosis and post-fracture quality measures is not consistent despite the existence of several NCQA and CMS healthcare provider quality measures. The solution to resolving the 75 …
Host: Matt Birnholz, MD
This session of Grand Rounds Nation is provided by the American College of Osteopathic Family Physicians (ACOFP), and features Dr. Susan Zito, DO, MPH. Dr. Zito is a faculty physician at the Largo Medical Center in Largo, Florida.
This is Part 1 of a lecture in two parts.
Part 2 >>
Host: Brian P. McDonough, MD, FAAFP
Guest: Steven T. Harris, MD, FACP
Join host Dr. Brian McDonough as he welcomes Dr. Steven Harris, Clinical Professor of Medicine from the University of California-San Francisco, to discuss the practice guidelines in preventing osteoporotic fracture and the appropriate treatments to prevent additional fractures. He will also address how to best ensure patient compliance.
Download and listen today!
Host: Matt Birnholz, MD
Guest: Michael Lewiecki, MD, FACP, FACE
Anyone in medicine will freely admit that osteoporosis is a major health threat in the United States, and yet the majority of patients with osteoporosis remain undiagnosed and untreated. In fact, fewer than one-third of cases have even been diagnosed, and only 14% of women with osteoporosis receive treatment. This comes in stark contrast to the fact that more than 50% of women over age 50 will encounter an osteoporosis-related fracture. So what can the healthcare community do in the face of those odds? Addressing this issue is Dr. Michael Lewiecki, Osteoporosis Director at the New Mexico Clinical Research and Osteoporosis Center. He's also Clinical Assistant Professor of Medicine at the University of New Mexico School of Medicine. Dr. Matt Birnholz hosts.
Host: Eric Tangalos, MD
Guest: Alexandra Papaioannou, MD
Millions of Americans have osteoporosis, but too often, a broken bone is the first indication of this common condition. What osteoporosis screening strategies can help diagnose osteoporosis in its early stages, and what treatment regimens are the most effective? Dr. Alexandra Papaioannou, professor in the department of medicine, and past-director of the division of geriatric medicine with a joint appointment in the division of rheumatology at McMaster University in Ontario, Canada, says it's important to target and prevent both falls and osteoporosis in tandem to reduce fractures. What are optimal amounts of calcium and vitamin D for older, less mobile patients? How can long term care facilities incorporate osteoporosis prevention into their screenings? Dr. Eric Tangalos hosts.
Guest: Rachel Kim, MD
Host: Steven Edelman, MD
Diabetes may affect the musculoskeletal system in a variety of ways. The metabolic perturbations in diabetes result in changes in the connective tissue. What are current recommendations for healthcare providers as an overall strategy in the treatment of patients living with diabetes? Join host Dr. Steven Edelman and his guest, rheumatologist at the Scripps Clinic, Dr. Rachel Kim, as they discuss musculoskeletal complications, intervention and treatment.
Host: Mark Nolan Hill, MD
Guest: Anthony Miniaci, MD
Early arthritis of the knee is a frustrating and painful condition, especially for our more active patients. Some will begrudgingly accept the end of their adult sports league careers, others will be less inclined to hang up their sneakers. In this case, depending on the severity of the condition, there could be several procedural options, including a new arthroscopic resurfacing technique for those with less severe arthritis: could this be the quickest route back to the playing field? Dr. Anthony Miniaci, executive director of Cleveland Clinic Sports Health and one of the developers of this new procedure, explains why this procedure could be the answer for patients who have failed all biologic procedures, but are not yet ready for a total knee replacement. Which of your patients might be a candidate? Dr. Mark Nolan Hill hosts.
Host: Lisa Mazzullo, MD
Guest: Jane Salmon, MD
Twenty years ago, women who suffered from lupus were discouraged from having children; today women with lupus are successfully having healthy babies. Doctors have found that counseling lupus patients prior to conception significantly increases the chances of a healthy pregnancy. Dr. Jane Salmon, professor of medicine at Weill Medical College in New York, joins host Dr. Lisa Mazzullo to talk about her groundbreaking research for pregnant women dealing with this autoimmune disease.
Host: Lee Freedman, MD
Guest: John Carey, MB, BCh, BAO
What are the mechanisms that are suspect for increasing incidence of osteonecrosis of the jaw in those taking bisphosphonates? Is this a significant risk? Dr. John Carey, consultant physician in internal medicine and rheumatology at Galway University Hospitals, reviews the evidence potentially modifying or increasing the risk of patients developing osteonecrosis of the jaw if they take bisphosphonates. Do patients need an oral exam before they begin taking bisphosphonates? Dr. Lee Freedman hosts.
Host: Lee Freedman, MD
Guest: Frederick Vivino, MD
Sjogren's syndrome is a commonly overlooked autoimmune disorder. Dry eyes and whole-body dryness are just two of the symptoms of Sjogren's syndrome that can suggest other conditions as well. How does Sjogren's present itself beyond dry eyes, and how severe is the condition? Dr. Frederick Vivino, clinical associate professor of medicine at the University of Pennsylvania School of Medicine, describes some of the tests and therapies available for Sjogren's syndrome to host Dr. Lee Freedman.
Produced in Cooperation with
Host: Mary Leuchars, MD
Guest: Brian Kelly, MD
In sports medicine, the hip has traditionally received less attention from physicians than other joints. What are the types of non-arthritic hip pain that clinicians need to recognize in order to make accurate diagnoses for both recreational and professional athletes? Dr. Brian Kelly, assistant professor of orthopedic surgery at the Weill Medical College of Cornell University and attending physician at the Hospital for Special Surgery in New York, examines this issue from two vantage points: as clinician researcher, and as team physician for the NFL's New York Giants. Dr. Mary Leuchars hosts.
Guest: David Felson, MD, MPH
Host: Mark Nolan Hill, MD
A patient in your office describes the knee pain they have been feeling for an extended period of time. The MRI that you order on their knee reveals meniscal damage. New research is telling us that meniscal tears may be more common than we realize, and further, raises questions as to whether the meniscal tear is really the source of your patient's knee pain. Dr. David Felson, professor of medicine at the Boston University (BU) School of Medicine and professor of epidemiology at the BU School of Public Health, explains that damaged meniscal cartilage may not be directly linked to knee pain. Dr. Mark Nolan Hill hosts.
Guest: Paul Howard, MD
Host: Larry Kaskel, MD
Other than the name, Doctor-Prescribed steroids have little in common with the steroids that often get bad rap from athletic abuse. Our guest today, Dr. Paul Howard, President of Arthritis Health begins the conversation explaining the differences between anabolic and medical steroids. He and host, Larry Kaskel MD, talk about the various types of steroids, when they should be used, and for how long they can be used. They also explore the differences between Disease Modifying Agents (DMA's) and steroids.
Host: Bill Rutenberg, MD
Guest: Brian Berman, MD
What benefit does acupuncture offer in the treatment of osteoarthritis? Our guest Dr. Brian Berman, Professor of Family Medicine and the founder and director of the University of Maryland Center for Integrative Medicine shares his research supporting the hypothesis that patients with osteoarthritis benefit significantly from acupuncture treatments. In this segment, Dr. Berman talks with host Dr. Bill Rutenberg about the initial experiments which led to NIH funded trial. Learn of the outcomes of this trial including how many treatments are required to have an impact on the patient and what researchers have learned from following the patients after the trial.
Host: Susan Dolan, RN, JD
Guest: Richard Blau, MD
Dr. Richard H. Blau is the founder and Medical Director of The Arthritis Institute of Long Island in Long Island, New York and a Founding Fellow of the American College of Rheumatology. Hear Dr. Blau as he discusses his book, Too Young to Feel Old: The Arthritis Doctor's 28-Day Formula for Pain-Free Living.
Host: Lee Freedman, MD
Guest: Craig Israelite, MD
Dr. Israelite intially reviews some basic concepts in the approach to osteoarthritis. He then outlines recent surgical advances in the treatment of osteoarthritis of the hip that have led to better outcomes for our patients. These include minimally invasive surgery, progress in postoperative rehabilitation and the development of new bearing surfaces that both improve range of motion and extend the life of the hip prosthesis.
Guest: Goncalo Abecasis, PhD
Host: Paul Raeburn
Host Paul Raeburn interviews Goncalo Abecasis, PhD, associate professor of biostatistics at the University of Michigan School of Public Health, about the link between height and arthritis. What we can learn about the genetics of height from this connection?
Guest: Paul Lux, MD
Host: Mark Nolan Hill, MD
What causes arthritis? Is it wear and tear or genetics? What are the best solutions for arthritis of the knee, hip and shoulder? Join Dr. Mark Hill interview Dr. Paul Lux, orthopedic surgeon and expert on joint replacement on the topic of arthritis.
Host: Susan Dolan, RN, JD
Guest: Jacob Teitelbaum, MD
Over 40 Million Americans suffer from arthritis. Join Dr. Jacob Teitelbaum, Director of the Fibromyalgia and Fatigue Centers, based in Dallas, Texas, and author of "Pain Free 1-2-3: A Proven Program for Eliminating Chronic Pain Now," discuss his 4-step natural program to treat arthritis.
Guest: Brett Summey, MD
Host: Leslie P. Lundt, MD
In this segment, Dr. Brett Summey discusses the diagnosis and treatments for cutaneous lupus.
Host: Larry Kaskel, MD
Guest: Elizabeth Tieman, MD
Work-life balance: how many of us can say we have it, let alone come close to having it? Board-certified radiologist Dr. Betsy Tieman is one healthcare professional who can say she achieved work-life balance by leaving private practice where she was working 14 hours a day to take advantage of locum tenens work, which also enabled her to train and compete in triathlons.
Guest: J. Lee Nelson, MD
Host: Michael Benson, MD
Rheumatoid Arthritis often improves during pregnancy. Why? Truth is stranger than fiction here as it appears that immunologically competent fetal cells leaking into the maternal circulation moderate the maternal immune response to "self."
Guest: Patience White, MD
Host: Laura Humphrey, PhD
Dr. Patience White, Chief Public Health Officer for the Arthritis Foundation and Professor of Medicine and Pediatrics at the George Washington University School of Medicine and Health Sciences talks about how the prevalence of arthritis has changed over the years and the cost it now poses to the U.S. economy.